We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+11.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$10.6B
AUM Growth
+$1.17B
(+12%)
Cap. Flow
+$3.01B
Cap. Flow
% of AUM
28.27%
Top 10 Holdings %
Top 10 Hldgs %
22.3%
Holding
850
New
52
Increased
273
Reduced
342
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$96.9M |
| 2 |
Merck
MRK
|
+$73.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$57.1M |
| 4 |
Illumina
ILMN
|
+$40.4M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$57.2M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$51.7M |
| 3 |
Kimberly-Clark
KMB
|
+$28.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$26.5M |
| 5 |
Arista Networks
ANET
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.77% |
| 2 | Technology | 20.35% |
| 3 | Consumer Discretionary | 9.49% |
| 4 | Communication Services | 7.69% |
| 5 | Financials | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Trex
TREX
$4.56B
| $10.2M | 0.1% |
142,629
+23,393
| +20% | +$1.62M |
|
|
BHVN
227
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $10.2M | 0.1% |
156,887
-15,912
| -9% | -$1.04M |
|
228
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.85B
| $10.1M | 0.09% |
238,844
+50,692
| +27% | +$1.89M |
|
229
T. Rowe Price
TROW
$25.6B
| $10.1M | 0.09% |
78,736
-8,344
| -10% | -$1.1M |
|
230
ExxonMobil
XOM
$651B
| $10M | 0.09% |
291,691
-523,374
| -64% | -$21.4M |
|
231
Verisk Analytics
VRSK
$26.1B
| $9.99M | 0.09% |
53,928
+9,637
| +22% | +$1.76M |
|
232
Costco
COST
$423B
| $9.99M | 0.09% |
28,130
-2,398
| -8% | -$806K |
|
233
Workday
WDAY
$39B
| $9.96M | 0.09% |
46,293
+33,898
| +273% | +$6.71M |
|
234
Charles River Laboratories
CRL
$11.3B
| $9.93M | 0.09% |
+43,846
| New | +$9.1M |
|
|
ETFC
235
DELISTED
E*Trade Financial Corporation
ETFC
| $9.85M | 0.09% |
196,829
-1,443
| -0.7% | -$75.3K |
|
236
Colgate-Palmolive
CL
$73.3B
| $9.81M | 0.09% |
127,115
+5,819
| +5% | +$444K |
|
|
TWTR
237
DELISTED
Twitter, Inc.
TWTR
| $9.78M | 0.09% |
+174,127
| New | +$6.68M |
|
|
HES
238
DELISTED
Hess
HES
| $9.73M | 0.09% |
237,748
+212,590
| +845% | +$10.1M |
|
239
MetLife
MET
$62.5B
| $9.73M | 0.09% |
261,791
+7,297
| +3% | +$277K |
|
|
HOLI
240
DELISTED
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
| $9.73M | 0.09% |
880,226
-11,222
| -1% | -$133K |
|
|
IGMS
241
DELISTED
IGM Biosciences
IGMS
| $9.62M | 0.09% |
130,287
-6,081
| -4% | -$360K |
|
|
MOR
242
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $9.53M | 0.09% |
303,682
+36,932
| +14% | +$1.2M |
|
|
MXIM
243
DELISTED
Maxim Integrated Products
MXIM
| $9.48M | 0.09% |
140,220
+131,473
| +1,503% | +$8.9M |
|
244
Honeywell
HON
$76.7B
| $9.48M | 0.09% |
61,088
-51,046
| -46% | -$7.59M |
|
245
Insmed
INSM
$22B
| $9.38M | 0.09% |
292,000
| – | – |
|
|
EIDX
246
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $9.38M | 0.09% |
185,721
| – | – |
|
247
EPAM Systems
EPAM
$5.42B
| $9.15M | 0.09% |
28,300
-2,500
| -8% | -$746K |
|
248
Stryker
SYK
$133B
| $9.13M | 0.09% |
43,839
-1,021
| -2% | -$198K |
|
249
Pan American Silver
PAAS
$18.6B
| $9.13M | 0.09% |
284,000
-76,000
| -21% | -$2.61M |
|
|
SAGE
250
DELISTED
Sage Therapeutics
SAGE
| $9.13M | 0.09% |
+149,300
| New | +$7.57M |
|
Similar funds
PCM
A
MGP
LF
BPA
MIM
SPIA
Candriam SCA's Q3 2020 Portfolio in Review
As of Q3 2020, Candriam SCA held 850 positions worth $10.6B, up 12% from $9.47B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $3.01B of net new capital in Q3 2020, opening 52 new positions and adding to 273 existing holdings. Its largest new stake was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $57.2M trimmed.
- Candriam SCA's largest Q3 2020 buy was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
- Candriam SCA added most to Amgen in Q3 2020, an estimated $96.9M increase.
- Candriam SCA's biggest Q3 2020 reduction was Apple, cutting an estimated $57.2M.
- Candriam SCA fully exited G1 Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $21.1M.
- Candriam SCA's ten largest holdings make up 22% of its $10.6B portfolio in Q3 2020.
- Candriam SCA opened 52 new positions and closed 48 in Q3 2020.
- Candriam SCA's portfolio value rose 12% quarter-over-quarter to $10.6B.
Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.